STRENGTH

Technology platform

CorreGene has established leading platforms for TCR discovery and optimization.

TCR discovery platform can support acquisition of TCR for various optimal targets in large scale and low cost. In particular, the SMART-TCR affinity optimization platform, a revolutionary TCR affinity optimization technology, has greatly improved the success rate and efficacy of TCR affinity optimization and broken down the barriers of development TCR innovative drugs.

TCR targets (T cell epitopes) identification

T cell epitopes
  • •Deep mining of Omics data
  • •Cover all dominant HLA genotype
  • •Established tumor antigen database
  • •More than 50 prioritized T cell

Acquisition of natural TCRs

  • •High efficient, Low cost single-cell TCR cloning technology
  • •Large human tumor specific TCR Library
  • •High-throughput and high-content TCR screening assay

SMART-TCR affinity optimization system (core technology)

T cell epitopes
  • •High efficient SMART-TCR system based on T cell display
  • •TCR with off-target activity can be removed by built-in assay during screening
  • •Affinity optimized TCR screening based on T cell function
  • •Closed-loop system support quickly obtain affinity optimized TCRs

TCR clinical test

TCR clinical trial
  • •Advanced T cell CMC platform
  • •Cover all dominant HLA genotype
  • •High quality clinical resources
  • •More than 50 prioritized T cell epitopes under development

TCR preclinical research

  • •Allo-reactivity assay based on single HLA cell bank
  • •Preclinical safety evaluation
  • •TCR Specificity evaluation using X-Scan and primary cells killing assay
  • •Preclinical Pharmacokinetic (PK) Assays
  • •In vitro and in vivo antitumor activity

TCR-fusion protein format design

core technology
  • •TCR-fusion structure designed with AI assisted technology
  • •Prioritized new formats with excellent expression performance and potency